NCT04875806View on ClinicalTrials.gov

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

January 30, 2024

Study Completion Date

January 30, 2024

Conditions
Advanced or Metastatic Solid TumorsOvarian CancerNon-small Cell Lung CancerBreast Cancer
Interventions
DRUG

NC762

NC762 is an experimental antibody drug that may make the immune response more active against cancer

Trial Locations (8)

14263

Roswell Park Cancer Institute, Buffalo

15232

UPMC Hillman Cancer Center, Pittsburgh

17325

Gettysburg Cancer Center, Gettysburg

22031

Inova Schar Cancer Institute, Fairfax

28078

Carolina BioOncology Institute, Huntersville

60637

The University of Chicago Medicine and Biological Sciences, Chicago

06519

Yale Cancer Center, New Haven

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

NextCure, Inc.
All Listed Sponsors
lead

NextCure, Inc.

INDUSTRY

NCT04875806 - A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter